JD Health's revenue growth likely slowed in the first quarter, though demand should stay resilient, Nomura says in a note. The brokerage estimates revenue rose 17% on year in the first quarter, down from 27% growth in the fourth quarter, mainly because demand related to the peak of the flu season came earlier than usual. Nomura says pharmaceutical sales should remain supported by growth in prescription volumes and rising online penetration. Nomura maintains a buy rating and its target price of HK$80.00. Shares are HK$47.14. (tracy.qu@wsj.com)
JD Health's Revenue Growth Likely Slowed in First Quarter — Market Talk
Earlier from Jd Health International
- CF Pharmtech Announces Strategic Cooperation With JD Health
- JD Health International: Record revenue and profit growth driven by AI healthcare expansion and omnichannel strategy
- Hong Kong shares fall after Lunar New Year break, tech drops
- Asia report: Defence plays lead gains across the region